Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Withdrawn 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms by Site 2Neoplasms 2Multiple Myeloma 2Glioblastoma 2Digestive System Neoplasms 2Digestive System Diseases 2Thrombocythemia, Essential 1Sarcoma 1Rectal Diseases 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Diseases 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Leukemia, Myeloid, Acute 1Intestinal Neoplasms 1Intestinal Diseases 1Gliosarcoma 1Glioma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Colorectal Neoplasms 1Colonic Diseases 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Melphalan 16Cyclophosphamide 14Dexamethasone 13fludarabine phosphate 12Filgrastim 11Antilymphocyte Serum 11fludarabine 8Radiotherapy 8Mycophenolic Acid 8Cyclosporine 8Busulfan 8Whole-Body Irradiation 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Methylprednisolone 6Lenalidomide 6Bortezomib 6pomalidomide 5Rituximab 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Flow Cytometry 4Etoposide 4Arsenic Trioxide 4liposomal doxorubicin 3Thalidomide 3Surveys and Questionnaires 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Plasma Cell × Ascorbic Acid × Clear all
NCT00227682 2012-05-28

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡